Hospital
Jefferson County Hma LLC
Jefferson County Hma LLC was paid $14.31M by Medicaid between Jan 2018 and Dec 2024, across 89 billing codes. Its largest line is 99283, emergency room visit (moderate) — 44% of everything it billed.
33Billing provider infoJEFFERSON COUNTY HMA LLC
JEFFERSON CITY, TN 37760
JEFFERSON CITY, TN 37760
33aNPI1972585347assigned 11/18/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.31M
24GClaims255,577
24DCodes billed89
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#20 of 71
Median peer was paid$6.96M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,851 | $1.75M | |
| 2019 | 46,315 | $2.23M | |
| 2020 | 42,845 | $1.71M | |
| 2021 | 42,398 | $2.43M | |
| 2022 | 36,555 | $2.51M | |
| 2023 | 40,227 | $2.45M | |
| 2024incomplete | 22,386 | $1.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 44% | 29,535 | 26,304 | $6.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 19,936 | 16,946 | $4.94M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.7% | 4,556 | 3,635 | $1.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.1% | 4,343 | 3,935 | $586K |
| 87428 | 2.0% | 6,733 | 6,061 | $293K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.9% | 148 | 134 | $275K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 143 | 135 | $118K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,224 | 7,810 | $100K |
| G0378 | Hospital observation service, per hour | <1% | 1,009 | 578 | $87K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,403 | 21,839 | $66K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,591 | 3,806 | $41K |
| 80053 | Comprehensive metabolic panel | <1% | 20,332 | 16,685 | $41K |
77 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,699 | $40K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,670 | $37K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,679 | $30K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 251 | $28K |
| 84484 | <1% | 5,563 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 719 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,730 | $23K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,671 | $22K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,079 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,084 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,964 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,016 | $16K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,561 | $16K |
| 83690 | <1% | 5,411 | $14K | |
| 87081 | <1% | 4,982 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,063 | $12K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 244 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,319 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 978 | $7K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 25 | $6K |
| 81025 | <1% | 3,406 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,330 | $6K |
| 81001 | <1% | 8,616 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,284 | $4K |
| 80061 | Lipid panel | <1% | 1,904 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 273 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 850 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 137 | $2K |
| 83735 | <1% | 805 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 697 | $982.39 |
| 85610 | <1% | 974 | $847.24 | |
| 85730 | <1% | 744 | $835.61 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 507 | $809.15 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 32 | $783.09 |
| 87807 | <1% | 200 | $748.51 | |
| 83880 | <1% | 184 | $608.02 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 60 | $546.03 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 90 | $508.44 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,879 | $453.62 |
| 85027 | <1% | 238 | $307.00 | |
| 82550 | <1% | 267 | $298.12 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 15 | $266.37 |
| 85379 | <1% | 59 | $199.20 | |
| 82607 | <1% | 88 | $193.80 | |
| 83605 | <1% | 54 | $166.16 | |
| 86900 | <1% | 62 | $132.36 | |
| 86850 | <1% | 61 | $126.89 | |
| 80076 | <1% | 62 | $113.88 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,183 | $106.19 |
| 87040 | <1% | 55 | $101.45 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 79 | $88.45 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,421 | $84.42 |
| 81003 | <1% | 243 | $72.90 | |
| 86141 | <1% | 28 | $72.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,804 | $64.45 |
| 73610 | <1% | 13 | $60.76 | |
| 84439 | <1% | 31 | $58.92 | |
| 72100 | <1% | 13 | $57.39 | |
| 86901 | <1% | 62 | $56.20 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,230 | $38.02 |
| 94760 | <1% | 140 | $37.56 | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 74 | $36.53 |
| 82553 | <1% | 46 | $27.76 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 46 | $19.96 |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 27 | $18.81 |
| 82962 | <1% | 89 | $6.53 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 62 | $2.88 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,408 | $0.00 |
| 96376 | 0% | 43 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 251 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 61 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 116 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 587 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 501 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 132 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 129 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 164 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.